1244016-74-7

Upstream product

• 63697-96-1 4-Ethynylbenzaldehyde 
• 183677-71-6 2-(4-bromophenyl)-5,5-dimethyl-1,3,2-dioxaborinane 
• 5572-94-1 5,5-dimethyl-2-(4-iodophenyl)-1,3,2-dioxaborinane 

Downstream Products

• 1244016-75-8 4-(4-((4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)ethynyl)benzyl)morpholine 
• 1244017-40-0 methyl 6-{4-[(4-formylphenyl)ethynyl]phenyl}pyridine-2-carboxylate 
• 1244018-24-3 methyl 4-{4-[(4-formylphenyl)ethynyl]phenyl}pyridine-2-carboxylate 

Relevant academic research and scientific papers

Bright fluorescent purine analogues as promising probes

Modified bright fluorescent nucleosides that respond to the microenvironment have great potential as probes. A series of novel 8-(phenylethynyl)phenylated 2-amino-2′-deoxyadenosine and 2′-deoxyisoguanosine derivatives have been synthesized by Sonogashira-type coupling reaction and Suzuki reaction. The maximum emission of the new compounds is in the visible region, with strong solvatochromicity and pH-dependent fluorescent properties. Furthermore, some of them exhibit bright fluorescence emissions in various solvents (ε × Φ = 4000–39,000 cm?1 M?1). These consequences indicate that purine analogues could respond to the microenvironment and serve as promising fluorescent probes. Supplemental data for this article is available online at https://doi.org/10.1080/15257770.2021.2004418.

HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS

The invention relates to chemical compounds of formula (IB): or a salt thereof. In some embodiments, the invention relates to inhibitors of UDP-3-0 — (R-S-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC). In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein and their use in the prevention and/or treatment of Gram- negative bacterial infections.